KNOWLEDGE BANK

Interviews

Innovation Management at Bachem

Chief Technology Officer, Bachem Holding AG
Gnther Loidl joined Bachem in He held several functions in Research and Development RD and Active Pharmaceutical Ingredient Manufacturing and became Vice President RD in Since he is CTO of the Bachem Group and a member of the Corporate Executive Committee He studied chemistry in Regensburg Germany and Leeds UK and obtained his doctorate under the supervision of Luis Moroder at the Max Planck In...

Articles

Rethinking How Medicines Work

A visit to the doctors office often begins with routine questions Age weight blood pressure current medications and medical history are all taken note of These questions may appear simple but they are central to determining the dosage of a medicine someone might be prescribed

Research Insights

Baseline Characteristics of SARS-CoV-2 Vaccine Non-responders in a Large Population-based Sample

Individuals with certain malignancies organ transplant recipients and immunecompromised individuals could mount either an incomplete or suboptimal antibody response to primary series vaccination

Case Studies

High Concentration Antibody - Rituximab

Challenge Antibodies tend to aggregate at the high concentrations typically required for their therapeutic application The key challenge of this study was to reduce the rate of aggregation in isotonic aqueous formulation of rituximab at mgml whilst maintai

Techno Trends

China's New Drug Approval Regulations Aim to Expedite Market Entry for Biologics

New regulations in China are designed to accelerate the approval process for biologics

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Artificial Intelligence

Mansi Athalye

Assistant Professor, Department of Pharmaceutics, L. M.College of Pharmacy

Daryai Uma Ghanshyam

L. M.College of Pharmacy

2

Decoding Antisense Oligonucleotides: Mechanisms, Applications, and Future Directions

Dr. Arun Shastry

Dr. Arun Shastry is a Bengaluru-based scientist with a PhD in Immunogenetics. He is the Co-Founder, Managing Director, and Chief Scientific Officer (CSO) of Hanugen Therapeutics, a pioneering biopharmaceutical company focused on oligonucleotide-based therapies for rare genetic diseases, particularly Duchenne Muscular Dystrophy (DMD). With over two decades in drug discovery for rare disorders, Dr. Shastry drives affordable, accessible treatments through innovative personalized medicine approaches in India.

3

Peptide-Drug Conjugates in Precision Oncology

Dr. Keykavous Parang

Dr. Keykavous Parang is a professor at Chapman University with expertise in peptide-based therapeutics and targeted drug delivery systems. He has published extensively in bioconjugate chemistry and nanomedicine, focusing on translating innovative molecular platforms into clinically viable cancer treatments.

Thuy Do

Thuy Do is a Pharm.D. student at Chapman University School of Pharmacy with research interests in nanomedicine and cancer therapeutics. She is involved in Dr. Parang’s capstone project, focusing on peptide-based conjugates and nanoparticle drug delivery systems for the development of innovative targeted cancer treatments.

Clare Dinh

Clare Dinh ('27) is a second-year PharmD student at Chapman University with a leadership emphasis. Active in various professional organizations, she is passionate about pharmaceutical research and plans to pursue postgraduate residency or fellowship programs to further her professional career.

Mahsa Moazen

Mahsa Moazen is a PharmD student at Chapman University and a researcher in Dr. Parang’s peptide drug conjugates project. She earned her bachelor’s degree in Pharmaceutical Chemistry. Her academic interests focus on peptide conjugates for targeted cancer therapy, bridging pharmaceutical research and clinical practice to advance innovative drug development.”

Troy Khong

Troy Khong is a PharmD student at Chapman University School of Pharmacy, set to graduate with a Pharm.D. with a Leadership Degree Emphasis in 2027. I am excited to continue growing in the field of pharmacy and look forward to pursuing opportunities related to pharmaceutical industry.

4

Trump Tariff Tyranny and Pharma Preparedness

Dr. M Aamir Mirza

Dr. M. Aamir Mirza is working as an Assistant Professor in the Department of Pharmaceutics, Jamia Hamdard, an NIRF Rank 1 institute and a NAAC ‘A+” grade deemed to be University. He has a multifaceted career portfolio adorned with both industry and academic accomplishments. During his industry stay he became a seasoned scientist and dealt with challenging NCE/NDA development. He is on advisory boards of some international research-based companies of India, New Zealand and Europe. Academics and Research being close to his heart, he has published more than 110 manuscripts in the journals of international repute and has been granted 02 Indian patent and filed for 04. He has contributed several chapters in books published by reputed authors like Elsevier and Bentham. He is amongst the very few scientists globally who has an expertise in Humic substances research. A well-travelled scientist; he has delivered scientific addresses in countries like USA, Austria, Japan, Netherlands, Turkey, Estonia, Spain and Russia. He has been Elite Fellow at University of Malaya (Malaysia) for the last 5 years where he takes classes on the topics related to industrial pharmacy.

5

Navigating Regulatory Frameworks: “Generic Approvals in Latin America’s Two Giants- Brazil & Mexico

Bhavya Sridevi Sundaraneedi

Sundaraneedi Bhavya Sridevi is a Master’s student of Regulatory Affairs at National Institute of Pharmaceutical Education and Research (NIPER- Raebareli). She had a six-month internship experience at Hetero Labs in Regulatory affairs of Latin America. Her interests include global regulatory affairs and Latin American emerging market regulations.

Dr. Rahul Shukla

Dr. Rahul Shukla, Assistant Professor at the Department of Pharmaceutics, NIPER Raebareli, Lucknow, an Institute of National Importance, under the Ministry of Chemicals & Fertilizers, Govt. of India. He was awarded SERB International Research Experience (SIRE) Fellow. Listed in Stanford University's Top 2% Scientists in Pharmaceutical Sciences Worldwide. 
Research Interest: Pharmaceutics, Nanomedicine, Particle Engineering, Bionanomaterials for various therapeutic applications.
 

press releasesRead more...

Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID®

Sanofi has partnered with NBA Champion KarlAnthony Towns to help raise awareness about the importance of COVID vaccination among those eligible during the respiratory season

ALK expands strategic tablet supply partnership with Catalent

ALK ALKBDC Nasdaq Copenhagen ALK B today announced that it has expanded its longstanding contract manufacturing partnership with Catalent Inc Catalent a leader in enabling the development

Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month

Piramal Pharma Solutions PPS a leading global Contract Development and Manufacturing Organization CDMO and part of Piramal Pharma Ltd PPL NSE PPLPHARMA BSE

OnDosis and Adare Pharma Solutions Announce Strategic Collaboration to Advance OnDosis's Lead U.S. ADHD Program

OnDosis AB OnDosis a Swedish life science company developing drug device combinations for precision dosing of oral solid medicines based on the Dosage Manager device platform and Adare Pharma

Expert Shares Why ADC Development is Demanding a New Level of Bioconjugation Expertise

Antibodydrug conjugates have moved from a promising concept to one of the most actively developed drug classes in oncology Behind that progress lies a manufacturing challenge that is becoming more demanding by the year

Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596

Hengrui Pharma SH HK today announced that it has entered into a license agreement with Novo Nordisk Novo for HRS a phase Iready glucagonlike peptide receptor GLPR

EventsRead more...

05 - 06

Oct 2026

ISPSAI France 2026

Paris, France

05 - 08

Oct 2026

12 - 13

Oct 2026

Pharmaceutics 2026

Village Hotel Changi, Singapor...

12 - 13

Oct 2026

2nd International Conference on Drug Discovery

Village Hotel Changi, Singapor...

14 - 15

Oct 2026

PDA Aseptic Manufacturing Excellence Conference

Pullman East Melbourne, Austra...

21 - 23

Oct 2026

21 - 22

Oct 2026

22 - 23

Oct 2026

PDA Aseptic Symposium 2026

Congress Square Nakanoshima, O...

LATEST NEWSRead more...

Regeneron and Sanofi Expand Collaboration to Develop Long-Acting Immunology Antibodies

Regeneron Pharmaceuticals and Sanofi have expanded their longstanding antibody collaboration to develop and commercialise a new group of longacting immunology treatments

SK pharmteco Announces $200 Million Investment to Expand Manufacturing Capacity

SK pharmteco has announced a fiveyear investment of more than million to expand and upgrade its development and manufacturing capabilities in the US focusing on small molecules and peptides

CAS and Novartis Collaborate to Advance AI-Ready Reaction Data

CAS has announced a collaboration with Novartis Biomedical Research to improve access to reaction data and support the use of artificial intelligence in scientific research

AbbVie Partners with Valkai to Expand AI Use in Clinical Development

AbbVie has partnered with Valkai to expand the use of AI across selected areas of clinical development

Turbine and Daiichi Sankyo Expand ADC Discovery Collaboration

Turbine and Daiichi Sankyo have expanded their collaboration to support antibodydrug conjugate ADC discovery using computational modelling

TriSalus Receives FDA Clearance for TriNav Advance for Liver Embolisation

TriSalus Life Sciences has received k clearance from the US Food and Drug Administration FDA for TriNav Advance a new device within its PressureEnabled Drug Delivery PEDD portfolio for liverdirected embolisation procedures